Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | G6PD | P11413 | 1/20 | 0.55 |
| ▸ | IDE | P14735 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30184665 | 1.00 | SMN1; SMN2 (0.59) | SMN1; SMN2MAPTG6PDIDEALDH1A1 | |
| SCHEMBL3259829 | 0.86 | TSHR (0.68) | MAPTALDH1A1CYP3A4TSHRTDP1 | |
| SCHEMBL23624934 | 0.85 | MAPT (0.52) | SMN1; SMN2MAPTG6PDIDEALDH1A1 | |
| SCHEMBL30291384 | 0.85 | MAPT (0.55) | MAPTALDH1A1CYP3A4TSHRTDP1 | |
| SCHEMBL8777970 | 0.85 | MAPT (0.55) | MAPTALDH1A1CYP3A4TSHRTDP1 | |
| SCHEMBL3344604 | 0.85 | CA1 (0.65) | SMN1; SMN2MAPTG6PDIDEALDH1A1 | |
| SCHEMBL14988893 | 0.83 | MAPT (0.54) | MAPTALDH1A1CYP3A4TSHRTDP1 | |
| SCHEMBL155420 | 0.83 | MAPT (0.54) | MAPTALDH1A1CYP3A4TSHRTDP1 | |
| SCHEMBL14988892 | 0.83 | MAPT (0.54) | MAPTALDH1A1CYP3A4TSHRTDP1 | |
| SCHEMBL30556228 | 0.83 | MAPT (0.54) | MAPTALDH1A1CYP3A4TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108527-A1 | POLO LIKE KINASE 4 INHIBITORS | ORIC PHARMACEUTICALS INC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4605392-A1 | METHODS FOR TREATING CANCER | Antares Therapeutics, Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| EP-4598912-A1 | POLO LIKE KINASE 4 INHIBITORS | Oric Pharmaceuticals, Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| WO-2025136811-A1 | CHEMICAL COMPOUNDS AND USES THEREOF | IDEAYA BIOSCIENCES, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025085725-A1 | METHODS FOR TREATING A P53-ASSOCIATED CANCER | SCORPION THERAPEUTICS, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| US-12240844-B2 | Pyrrolopyridine derivative and use thereof in prevention and treatment of protein kinase-related disease | VORONOI, INC. (KR) | 2025-03-04 | — | — | US | disclosed |
| US-20240400591-A1 | COMPOUNDS TARGETING MUTANT OF P53 | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-12-05 | — | — | US | disclosed |
| US-20240270699-A1 | COMPOUNDS HAVING N-ARYLPYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC AGENTS | LOMOND THERAPEUTICS, INC. | 2024-08-15 | — | — | US | disclosed |
| WO-2024086809-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| WO-2024076891-A1 | POLO LIKE KINASE 4 INHIBITORS | ORIC PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| US-6727238-B2 | CYCLOOXYGENASE INHIBITORS | PFIZER INC. | 2004-04-27 | — | — | US | disclosed |
| US-20030225064-A1 | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents | ANDO KAZUO (JP) | 2003-12-04 | — | — | US | disclosed |
| US-6608095-B2 | Sulfonylbenzene and sulfonamidobenzene compounds which inhibit COX-2; treatment of a medical condition in which prostaglandins are implicated as pathogens | PFIZER INC. | 2003-08-19 | — | — | US | disclosed |
| US-20020045654-A1 | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents | ANDO KAZUO (JP) | 2002-04-18 | — | — | US | disclosed |
| US-6294558-B1 | ANTIINFLAMMATORY AGENTS AND PROSTAGLANTINS | PFIZER INC. | 2001-09-25 | — | — | US | disclosed |
| EP-1086097-A1 | SULFONYLBENZENE COMPOUNDS AS ANTI-INFLAMMATORY/ANALGESIC AGENTS | PFIZER INC. (US) | 2001-03-28 | — | — | EP | disclosed |
| WO-1999064415-A1 | SULFONYLBENZENE COMPOUNDS AS ANTI-INFLAMMATORY/ANALGESIC AGENTS | PFIZER PHARMACEUTICALS INC. (JP) | 1999-12-16 | — | — | WO | disclosed |
| EP-0009164-B1 | DIAGNOSTIC AGENT AND ITS USE IN THE DETECTION OF UROBILINOGEN | BEHRINGWERKE Aktiengesellschaft (DE) | 1982-12-15 | — | — | EP | disclosed |
| US-4290771-A | DIAZONIUM SALT | BEHRINGWERKE AKTIENGESELLSCHAFT (DE) | 1981-09-22 | — | — | US | disclosed |
| EP-0009164-A1 | Diagnostic agent and its use in the detection of urobilinogen | BEHRINGWERKE Aktiengesellschaft (DE) | 1980-04-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240270699-A1 | COMPOUNDS HAVING N-ARYLPYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC AGENTS | IRAK3, IRAK1, IRAK2 | SMN1; SMN2 1579/4885MAPT 1830/4885G6PD 2705/4885 |
| US-12240844-B2 | Pyrrolopyridine derivative and use thereof in prevention and treatment of protein kinase-related disease | CLK1, CLK2, CLK3 | SMN1; SMN2 1836/4885MAPT 359/4885G6PD 2669/4885 |
| US-20260108527-A1 | POLO LIKE KINASE 4 INHIBITORS | PLK4, PLK2, PLK3 | SMN1; SMN2 3896/4885MAPT 3633/4885G6PD 2710/4885 |
| US-20020045654-A1 | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents | CNR1, PTGER1, PTGS1 | SMN1; SMN2 3119/4885MAPT 4790/4885G6PD 3810/4885 |
| US-20240400591-A1 | COMPOUNDS TARGETING MUTANT OF P53 | TP53, TP53BP1, MDM2 | SMN1; SMN2 4553/4885MAPT 2352/4885G6PD 460/4885 |
| US-20030225064-A1 | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents | CNR1, PTGS1, PTGER1 | SMN1; SMN2 3006/4885MAPT 4779/4885G6PD 3836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.